Supracervical Hysterectomy at Sacrocolpopexy
Supracervical (subtotal) hysterectomy removes the uterine corpus and retains the cervix. At sacrocolpopexy, the retained cervix provides an attachment site without creating a vaginal cuff. This is distinct from hysteropexy, which preserves the uterus. Ovarian conservation is a separate decision.
Both supracervical and total hysterectomy are options when hysterectomy accompanies sacrocolpopexy. Some studies associate cervical preservation with fewer mesh complications, but large contemporary cohorts have produced differing results. A universal mesh-exposure advantage, or equal long-term prolapse recurrence, has not been established for every technique and patient. Choose the operation using uterine and cervical findings, the patient's preferences, the extraction plan and the accompanying prolapse repair.[1][2][3][4]
Selection and Counseling
- Confirm that the patient wants hysterectomy as part of repair; discuss an appropriate uterine-preserving option when there is no separate indication for hysterectomy. See Principles of Prolapse Repair.
- Review uterine symptoms, cervical history, examination and cervical screening status. Investigate abnormal uterine or postmenopausal bleeding and suspicious findings before choosing a benign hysterectomy or tissue-fragmentation plan.
- Explain that the cervix remains and screening follows the patient's age, history and applicable guidelines. A universal requirement for both a new normal cytology result and a negative HPV result is inappropriate.
- Discuss ongoing cyclic bleeding, possible later cervical treatment, and the absence of established urinary, bowel or sexual-function benefit from retaining the cervix in randomized benign-hysterectomy evidence. These trials were not comparisons of hysterectomy type specifically at sacrocolpopexy.[5]
When cervical preservation is unsuitable
- Known or suspected uterine or cervical malignancy requires an appropriate oncologic plan rather than routine supracervical hysterectomy.
- Significant cervical disease, a history requiring specialist surveillance, unresolved bleeding, or inability to maintain indicated follow-up may favor another approach. Do not equate every remote low-grade screening abnormality with a permanent contraindication.
- Respect a preference for cervical removal after discussing the alternatives and their risks.[5][6]
Technique
Laparoscopic or robotic hysterectomy usually uses the same access as the planned sacrocolpopexy. The key decisions are:
- Adnexal management. Discuss opportunistic salpingectomy and decide on ovarian conservation separately, according to age, risk and preferences; see Opportunistic Adnexal Surgery.
- Safe dissection and vascular control. Establish the bladder and ureteral relationships before dividing pedicles or amputating the corpus. Adapt dissection to adhesions, uterine size and prior surgery.
- Cervical stump. Preserve suitable cervical tissue for the intended repair and confirm hemostasis. Endocervical treatment varies by technique; a fixed-depth thermal ablation recipe is not established by the comparative evidence, and treatment does not guarantee freedom from future bleeding.[5]
- Specimen extraction. Agree on the extraction route and any tissue fragmentation before surgery. Use the FDA restrictions below when considering laparoscopic power morcellation.[6]
- Complete the prolapse repair. Cervical retention does not replace adequate anterior and posterior vaginal support. Mesh dissection, fixation, sacral attachment, tension and peritoneal coverage belong to the Sacrocolpopexy technique. Avoid unintended vaginal penetration and bowel contact; peritoneal coverage cannot guarantee prevention of adhesions or bowel obstruction.
Power morcellation
Laparoscopic power morcellation remains an option for selected patients. The FDA recommends using a compatible, legally marketed containment system when power morcellation is appropriate. Do not use it with known or suspected malignancy; for presumed fibroids, do not use it in postmenopausal patients, those over 50, or patients suitable for intact vaginal or mini-laparotomy extraction. Discuss occult malignancy and alternatives. Containment reduces tissue dispersal but cannot eliminate every route of cancer spread.[6]
Comparative Evidence at Sacrocolpopexy
The following studies measured different outcomes. Mesh exposure on examination, a coded mesh complication and reoperation for a mesh complication are not interchangeable.
| Study | Population and endpoint | Finding and interpretation |
|---|---|---|
| Nassif 2022 systematic review | 19 studies; 10,572 women undergoing sacrocolpopexy with hysterectomy; mesh erosion | Lower odds with supracervical hysterectomy: pooled OR 0.26 (95% CI 0.18–0.38). Reported median point prevalences were 0.36% vs 3.8%; these are study-level summaries, not universal patient risks or fixed-time pooled incidences.[1] |
| Dallas 2022 California cohort | 12,189 minimally invasive sacrocolpopexies, including 3,371 concomitant supracervical and 5,027 total hysterectomies; mesh-complication reoperation | 0.7% vs 3.1%, with mean follow-up around three years; adjusted OR for total hysterectomy 4.20 (95% CI 2.72–6.50). This is an observational association, not a randomized comparison.[2] |
| Kikuchi 2023 MarketScan cohort | 3,463 women with at least two years of follow-up; coded complications and reoperations | No significant difference between supracervical and total hysterectomy in mesh complications (1.8% vs 1.5%) or prolapse reoperation (1.5% vs 1.1%). Subsequent cervical procedures occurred in 0.9% of the supracervical group.[3] |
| Glass Clark 2024 Premier cohort | 17,111 minimally invasive sacrocolpopexies with hysterectomy; coded mesh exposure over two years | Exposure was 47/6,708 (0.70%) vs 65/10,403 (0.62%), without a significant difference. Prolapse reoperation was 1.4% in both groups. Administrative data do not capture every asymptomatic examination finding.[4] |
These results support individualized counseling. A nonsignificant result does not establish equivalence, and short-term coded reoperation rates cannot substantiate an identical five-year anatomical recurrence rate. Hysterectomy type, surgical route and the choice between mesh and native-tissue support should be discussed as separate decisions.
Post-Operative Considerations
- Cervical screening: continue when indicated for a patient with a cervix; apply screening and surveillance criteria to the individual history. See Cervical Cancer Screening.
- Bleeding: recurrent or persistent bleeding needs assessment; do not automatically attribute new or postmenopausal bleeding to a benign stump. In the benign-hysterectomy Cochrane review, ongoing cyclic bleeding was more frequent after subtotal hysterectomy; its absolute frequency varied across trials.[5]
- Symptoms and support: assess bulge, urinary, bowel and sexual symptoms along with the examination. Cervix retention has not been shown to reliably improve these functional outcomes over total hysterectomy.[5]
- Later cervical procedures: these may be needed for bleeding or cervical disease; consider the existing mesh attachment when planning further surgery.[3]
See Also
- Sacrocolpopexy — the operation supracervical hysterectomy is paired with.
- Vaginal Hysterectomy — vaginal hysterectomy and the accompanying apical-support decision.
- Sacrospinous Hysteropexy — uterine-preservation alternative without hysterectomy.
- Manchester-Fothergill — vaginal uterine-preservation alternative.
- Principles of Prolapse Repair — the broader hysteropexy-vs-hysterectomy framework.
Videos
References
1. Nassif J, Yadav GS, Orejuela FJ, Turrentine MA. Rate of mesh erosion after sacrocolpopexy with concurrent supracervical compared with total hysterectomy: a systematic review and meta-analysis. Obstet Gynecol. 2022;140(3):412-420. doi:10.1097/AOG.0000000000004901.
2. Dallas K, Taich L, Kuhlmann P, et al. Supracervical hysterectomy is protective against mesh complications after minimally invasive abdominal sacrocolpopexy: a population-based cohort study of 12,189 patients. J Urol. 2022;207(3):669-676. doi:10.1097/JU.0000000000002262.
3. Kikuchi JY, Yanek LR, Handa VL, et al. Prolapse and mesh reoperations following sacrocolpopexy: comparing supracervical hysterectomy, total hysterectomy, and no hysterectomy. Int Urogynecol J. 2023;34(1):135-145. doi:10.1007/s00192-022-05263-w.
4. Glass Clark S, Bretschneider CE, Bradley MS, et al. Risk of postoperative mesh exposure following sacrocolpopexy with supracervical versus total concomitant laparoscopic hysterectomy. Int Urogynecol J. 2024;35(1):207-213. doi:10.1007/s00192-023-05658-3.
5. Lethaby A, Mukhopadhyay A, Naik R. Total versus subtotal hysterectomy for benign gynaecological conditions. Cochrane Database Syst Rev. 2012;(4):CD004993. doi:10.1002/14651858.CD004993.pub3.
6. US Food and Drug Administration. UPDATE: Perform only contained morcellation when laparoscopic power morcellation is appropriate: FDA safety communication. December 29, 2020. FDA guidance.